MURRAY HILL, N.J.--(BUSINESS WIRE)--Dec. 8, 2008--C. R. Bard, Inc. (NYSE: BCR) today announced that it has received
approval from the United States Food and Drug Administration to market
the E*LuminexxTM Vascular Stent. The device is a flexible,
self-expanding nitinol stent to be marketed by the Bard Peripheral
Vascular Division, located in Tempe, Arizona.
The E*Luminexx(TM) Vascular Stent is intended to treat
patients with common or external iliac artery occlusive disease. Current
estimates indicate that each year more than 140,000 patients are
candidates for iliac stent procedures in the United States. This patient
population is expected to grow by more than 10 percent annually due to
the increased clinician focus on treating peripheral arterial disease
and the growing number of diabetic patients who are at higher risk of
developing these occlusions.
Bard's prospective, multi-center, non-randomized, clinical study of 134
patients measuring the E*Luminexx(TM) Vascular Stent against
objective performance criteria demonstrated a 9-month primary patency of
94.03% and a site reported anatomic success rate (<30% final residual
stenosis) of 98.72%.
Timothy M. Ring, chairman and chief executive officer, commented, "The
E*Luminexx(TM) Vascular Stent joins the recently approved FlairTM
Endovascular Stent Graft to position Bard as the only medical device
company offering both a stent and a stent graft with peripheral vascular
indications in the U.S. The anticipated approval of the LifeStent(R)
FlexStar Stent for the treatment of superficial femoral artery disease
will further enhance our comprehensive offerings to address challenges
associated with the treatment of peripheral vascular disease."
C. R. Bard, Inc., (www.crbard.com)
is a multinational developer, manufacturer, and marketer of innovative,
life-enhancing medical technologies in the fields of vascular, urology,
oncology and surgical specialty products.
This press release may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, which
are based on management's current expectations, the accuracy of which is
necessarily subject to risks and uncertainties. These statements are not
historical in nature and use words such as "anticipate", "estimate",
"expect", "project", "intend", "forecast", "plan", "believe", and other
words of similar meaning in connection with any discussion of future
operating or financial performance. Many factors may cause actual
results to differ materially from anticipated results including product
developments, sales efforts, income tax matters, the outcomes of
contingencies such as legal proceedings, and other economic, business,
competitive and regulatory factors. The company undertakes no obligation
to update its forward-looking statements. Please refer to the Cautionary
Statement Regarding Forward-Looking Information in our September 30,
2008 Form 10-Q for more detailed information about these and other
factors that may cause actual results to differ materially from those
expressed or implied.
CONTACT: C. R. Bard, Inc.
Eric J. Shick, 908-277-8413
Vice President, Investor Relations
Holly P. Glass, 703-754-2848
Vice President, Government and Public Relations
Source: C. R. Bard, Inc.